Valvular Heart Disease News and Research

RSS

PCR London Valves 2015 to focus on innovative transcatheter therapies for valvular heart disease

For the first time in its 6-year history, PCR London Valves, the world's largest Course solely devoted to addressing the rapidly expanding and innovative field of transcatheter therapies for valvular heart disease, will be taking place in Berlin, Germany, from the 20 to 22 of September 2015.

29 Aug 2015

Noninvasive findings reduce catheterisation need in suspected PAH

Research shows that a risk score based on noninvasive measures can identify left heart failure in a “substantial percentage” of patients with suspected pulmonary arterial hypertension, reducing the need for right heart catheterisation.

15 May 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Training medical students on handheld ultrasound device can enhance their physical diagnosis

A new study by researchers from Icahn School of Medicine at Mount Sinai found that training medical students to use a handheld ultrasound device can enhance the accuracy of their physical diagnosis.

21 Nov 2014

Elsevier honored at BMA Medical Book Awards ceremony

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that 28 of its professional and scholarly products were honored at the British Medical Association's annual BMA Medical Book Awards ceremony at BMA House in London on Sept. 22, 2014.

25 Sep 2014

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures.

23 Sep 2014

Boston Scientific gains CE Mark, begins European commercial launch of 25 mm Lotus TAVI System

Boston Scientific Corporation has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

14 Jul 2014

Use of catheter ablation lowers risk for atrial fibrillation

Use of catheter ablation is not only beneficial for treating atrial flutter but also can significantly reduce hospital visits - both inpatient and emergency - and lower the risk for atrial fibrillation, according to research by UC San Francisco.

1 Jul 2014

Delays in receiving TAVR for severe aortic stenosis could impact effectiveness of treatment

Severe aortic stenosis (AS) has a grave prognosis with 25-50% of patients dying within a year once symptoms develop. Transcatheter aortic valve replacement (TAVR) represents a paradigm shift in the therapeutic options for these patients.

4 Jun 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Study of astronauts show heart becomes more spherical when exposed to microgravity in space

New findings from a study of 12 astronauts show the heart becomes more spherical when exposed to long periods of microgravity in space, a change that could lead to cardiac problems, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

31 Mar 2014

Class, ancestry and medication are factors in cardiac risk for lupus patients

New research published in Rheumatology, the international, peer-reviewed scientific journal, has suggested that systemic lupus erythematosus (SLE) patients of African descent and from lower socioeconomic groups face a higher risk of primary cardiac disease. However, those taking anti-malarial drugs reduce their risk.

16 Mar 2014

MHIF creates scientific program to address gaps in treating valvular heart disease patients

Despite significant medical advances, there continue to be significant gaps in the health care of the growing number of patients with valvular heart disease. In the USA, the total number of people aged 65 years or older with valvular heart disease will grow to approximately 5.2 million by year 2020, and 6.8 million individuals by the year 2030. The Minneapolis Heart Institute Foundation- has created a scientific program, "Valve Summit 2014: The Science and Delivery of Optimal, Multi-Disciplinary Care," to address the ongoing, complex evolution in the clinical management of patients with valvular heart disease. The conference will be held on April 25th and 26th at the Radisson Blu in downtown Minneapolis.

4 Dec 2013

Researchers identify link between narrowed heart valves and special lipoprotein in blood

Researchers at the University of Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link between narrowed heart valves and a special lipoprotein in the blood. In the long term, the research may well help to prevent valvular heart disease.

13 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Middle Peak Medical raises additional $3M in Series A financing

Middle Peak Medical, a development-stage medical device company that will commercialize a novel technology for treating mitral valve disease, has raised an additional $3M in a second closing of its over-subscribed Series A financing, which now totals approximately $11M.

28 Oct 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Echocardiographic screening does not reduce risk of death

A study in Norway suggests echocardiographic screening in the general public for structural and valvular heart disease was not associated with benefit for reducing the risk of death, myocardial infarction (heart attack) or stroke, according to a report published by JAMA Internal Medicine, a JAMA Network publication.

23 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013